SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
发明人:
PARK, Sung Woo,박성우,LEE, Ji Min,이지민
申请号：
KRKR2016/014654
公开号：
WO2017/105081A1
申请日:
2016.12.14
申请国别(地区):
WO
年份:
2017
代理人:
摘要：
A pharmaceutical composition for treating lung diseases or alleviating symptoms of lung diseases, according to the present invention, comprises a vacuolar-type H+-ATPase B2 (V-atpase B2) protein as an active ingredient. The pharmaceutical composition is useful for the treatment of lung diseases, particularly acute lung injury, pulmonary fibrosis or pulmonary emphysema, or alleviating symptoms thereof.Une composition pharmaceutique pour le traitement de maladies pulmonaires ou latténuation des symptômes de maladies pulmonaires, selon la présente invention, comprend une protéine H+-ATPase B2 de type vacuolaire (V-atpase B2) utilisée comme principe actif. La composition pharmaceutique est utile pour le traitement de maladies pulmonaires, en particulier dune lésion pulmonaire aiguë, dune fibrose pulmonaire ou dun emphysème pulmonaire, ou datténuer les symptômes de celles-ci.본 발명의 폐질환 치료용 또는 증상완화용 약학조성물은 V-에이티피아제 B2(V-atpase B2, Vacuolar-type H+-ATPase B2) 단백질을 유효성분으로 포함한다. 상기 약학조성물은 특히 폐질환 중에서 급성폐손상, 폐섬유화증 또는 폐기종의 치료 또는 증상 완화용으로 유용하다.
